Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Merck-and-Company stock (MRK)

Buy Merck-and-Company stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Merck-and-Company is a drug manufacturers - general business based in the US. Merck-and-Company shares (MRK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $103.09 – an increase of 2.46% over the previous week. Merck-and-Company employs 70,000 staff and has a trailing 12-month revenue of around $63.2 billion.

Our top picks for where to buy Merck-and-Company stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Complimentary access to a financial planner

Top pick for best mobile experience

Go to site
  • Trade $0 commission stocks, ETFs, and options with as little as $1
  • After-hours trading available
  • Earn 4.5% interest on uninvested cash with Gold
  • 24/7 customer support

How to buy Merck-and-Company stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – MRK. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Merck-and-Company stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.8 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.3 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Robinhood
Finder Score: 4.6 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Uphold
Finder Score: 3.6 / 5: ★★★★★
Crypto alternative
Uphold
★★★★★
Cryptocurrency
N/A
$0
4.65%
Get $10
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
Public.com
Finder Score: 4.4 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Merck-and-Company stock price (NYSE: MRK)

Use our graph to track the performance of MRK stocks over time.

Merck-and-Company shares at a glance

Information last updated 2024-12-04.
Latest market close$103.09
52-week range$94.48 - $133.74
50-day moving average $105.20
200-day moving average $119.60
Wall St. target price$130.33
PE ratio 21.3411
Dividend yield $3.04 (3.18%)
Earnings per share (TTM) $4.75

Is it a good time to buy Merck-and-Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Merck-and-Company price performance over time

Historical closes compared with the close of $103.09 from 2024-12-06

1 week (2024-12-02) 2.46%
1 month (2024-11-08) 0.17%
3 months (2024-09-09) -10.67%
6 months (2024-06-07) -21.11%
1 year (2023-12-08) -0.64%
2 years (2022-12-09) -0.06%
3 years (2021-12-09) 54.45%
5 years (2019-12-09) 41.75%

Is Merck-and-Company stock undervalued or overvalued?

Valuing Merck-and-Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Merck-and-Company's P/E ratio

Merck-and-Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Merck-and-Company shares trade at around 21x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Merck-and-Company's PEG ratio

Merck-and-Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0709. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Merck-and-Company's EBITDA

Merck-and-Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $22.9 billion.

The EBITDA is a measure of a Merck-and-Company's overall financial performance and is widely used to measure a its profitability.

Merck-and-Company financials

Revenue TTM $63.2 billion
Operating margin TTM 26.2%
Gross profit TTM $42.1 billion
Return on assets TTM 10.53%
Return on equity TTM 28.33%
Profit margin 19.23%
Book value $17.58
Market Capitalization $256.4 billion

TTM: trailing 12 months

Merck-and-Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Merck-and-Company's total ESG risk score

Total ESG risk: 28.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-Company's overall score of 28.35 (as at 12/31/2018) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Merck-and-Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Merck-and-Company's environmental score

Environmental score: 3.15/100

Merck-and-Company's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Merck-and-Company's social score

Social score: 15.55/100

Merck-and-Company's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Merck-and-Company's governance score

Governance score: 12.65/100

Merck-and-Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Merck-and-Company's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-Company hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Merck & Company Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.35
Total ESG percentile 47.16
Environmental score 3.15
Environmental score percentile 4
Social score 15.55
Social score percentile 4
Governance score 12.65
Governance score percentile 4
Level of controversy 3

Merck-and-Company share dividends

52%

Dividend payout ratio: 51.76% of net profits

Recently Merck-and-Company has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-Company shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Merck-and-Company's case, that would currently equate to about $3.04 per share.

Merck-and-Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Merck-and-Company's most recent dividend payout was on 7 January 2025. The latest dividend was paid out to all shareholders who bought their shares by 15 December 2024 (the "ex-dividend date").

Have Merck-and-Company's shares ever split?

Merck-and-Company's shares were split on a 1048:1000 basis on 2 June 2021 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-Company shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-Company shares which in turn could have impacted Merck-and-Company's share price.

Merck-and-Company share price volatility

Over the last 12 months, Merck-and-Company's shares have ranged in value from as little as $94.48 up to $133.7352. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-Company's is 0.411. This would suggest that Merck-and-Company's shares are less volatile than average (for this exchange).

Merck-and-Company overview

Merck & Co. , Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications.

Frequently asked questions

What percentage of Merck-and-Company is owned by insiders or institutions?
Currently 0.061% of Merck-and-Company shares are held by insiders and 79.44% by institutions.
How many people work for Merck-and-Company?
Latest data suggests 70,000 work at Merck-and-Company.
When does the fiscal year end for Merck-and-Company?
Merck-and-Company's fiscal year ends in December.
Where is Merck-and-Company based?
Merck-and-Company's address is: 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
What is Merck-and-Company's ISIN number?
Merck-and-Company's international securities identification number is: US58933Y1055
What is Merck-and-Company's CUSIP number?
Merck-and-Company's Committee on Uniform Securities Identification Procedures number is: 589339209

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site